Submitted August 23, 2007
Accepted October 9, 2007
Complete molecular response of e6a2 BCR-ABL positive acute myeloid leukemia to Imatinib then Dasatinib
David S Ritchie*, Michelle McBean, David A Westerman, Sergey Kovalenko, John F. Seymour, and Alexander Dobrovic
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Pathology, University of Melbourne, Parkville, Australia
* Corresponding author; email: david.ritchie{at}petermac.org.
De novo presentation of acute myeloid leukaemia (AML) expressing the Philadelphia (Ph) chromosomal abnormality is rare and is associated with a dismal prognosis. To date reported cases of Ph+ AML have expressed either the e13a2 or e14a2 BCR-ABL fusion transcripts. We report a unique case of de novo AML expressing the e6a2 fusion transcript and describe disease sensitivity to both Imatinib prior to allogeneic stem cell transplant (SCT) and Dasatinib for AML relapse after allogeneic SCT. Furthermore we report that sustained molecular remission has been achieved despite withdrawal of tyrosine kinase inhibitor therapy.
